SAN ANTONIO CENTER OF BIOMARKERS OF RISK FOR PROSTATE CANCER (SABOR)

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 前列腺癌是美国男性最常见的癌症。 现有的生物标志物-直肠指检（DRE）和PSA -敏感性和特异性较差。 来自前列腺癌预防试验和其他研究的数据表明，多种因素的组合-体质（例如，家族史，遗传变异），行为（例如，体重指数、饮食）以及体细胞（例如，GSTPi甲基化）-可以改善患有和没有前列腺癌的男性之间的区分。 圣安东尼奥前列腺癌风险生物标志物中心（SABOR）是一项以人群为基础的、少数人群和服务不足人群富集的队列研究，该研究收集了广泛的临床数据和生物标本，同时跟踪癌症相关结局，旨在发现、开发和验证前列腺癌风险的生物标志物。 迄今为止，在约3年的招募期内，共招募了3，142例男性，包括51%的西班牙裔或非裔美国人受试者。 利用SABOR的整个EDRN CEVC工作，我们发现了影响前列腺癌风险的几个因素，包括许多遗传变异（雄激素受体中的CAG重复长度、脑信号蛋白3B和3F、SRD 5A 2以及维生素D受体的变异）和体重指数（较高的值与较低的PSA水平相关）。 我们还发现，不同种族人群中前列腺癌的危险因素（热量摄入、脂肪摄入、微量营养素摄入、体重指数、水果和蔬菜摄入）存在显著差异，这些种族/种族人群中PSA和DRE的表现特征也不同。 在SABOR更新中，我们将完成队列中9，000名男性的招募，进一步探索这些行为，体质和躯体风险因素，开发和验证多变量前列腺癌风险算法，并进行EDRN网络验证研究。 SABOR的科学人员将继续在网络中担任领导职务，协助EDRN设计、实施和分析早期检测验证研究，这些研究将改变美国临床实践的护理标准。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most common cancer in U.S. men. Existing biomarkers - digital rectal examination (DRE) and PSA - have poor sensitivity and specificity. Data from the Prostate Cancer Prevention Trial and other studies suggest that a combination of factors - constitutional (e.g., family history, genetic variations), behavioral (e.g., body mass index, diet), as well as somatic (e.g., GSTPi methylation) - can improve the discrimination between men with and without prostate cancer. The San Antonio Center for Biomarkers of Risk of Prostate Cancer (SABOR) is a population-based, minority and underserved-enriched, cohort study that collects extensive clinical data and biospecimens while tracking cancer-related outcomes, designed to discover, develop, and validate biomarkers of prostate cancer risk. To date, 3,142 men have been enrolled over approximately 3 years of accrual including 51% Hispanic or African American subjects. Using the entire EDRN CEVC efforts of SABOR, we have found several factors that affect prostate cancer risk including a number of genetic variations (CAG repeat length in the androgen receptor, Semaphorins 3B and 3F, SRD5A2, and variations of the Vitamin D receptor) and body mass index (higher values associated with lower levels of PSA). We have also found substantial differences in risk factors for prostate cancer in different ethnic groups (caloric intake, fat intake, micronutrient intake, body mass index, fruit and vegetable intake) as well as different performance characteristics of PSA and DRE in these ethnic/racial groups. In the SABOR renewal, we will complete recruitment of 9,000 men in the cohort, explore further these behavioral, constitutional, and somatic risk factors, develop and validate a multivariable prostate cancer risk algorithm, and conduct EDRN Network validation studies. The SABOR scientific personnel will continue to serve in their leadership positions within the Network, assisting the EDRN with the design, conduct, and analysis of early detection validation studies that will alter the standard of care of clinical practice in the United States.